# Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression

**Authors:** Xin Li, Penghe Yang, Tianshi Wang, Peng Su, Chenmiao Zhang, Shen Fangyu, Huijie Yang, Jian Zhu, Xiaodong Tan, Ting Zhuang

PMC · DOI: 10.1038/s41419-025-08356-8 · Cell Death & Disease · 2026-01-21

## TL;DR

This study shows that USP8 and the Hippo/YAP axis work together in a feedback loop to promote the progression of triple-negative breast cancer.

## Contribution

The discovery of a positive feedback loop between USP8 and the Hippo/YAP axis in TNBC provides new insights into cancer progression mechanisms.

## Key findings

- USP8 stabilizes YAP by suppressing its K48-linked polyubiquitination.
- YAP enhances USP8 transcription by binding to its promoter region.
- USP8 inhibition reduces TNBC progression and correlates with poor patient survival.

## Abstract

The hyper-activation of the Hippo/YAP axis was observed in triple-negative breast cancer (TNBC), which was crucial for tumor progression. The over-activation of YAP in TNBC remains unexplained, despite the continued functionality of the inhibitory phospho-cascade. Recently, studies revealed that the ubiquitin modifications of YAP also play important roles in the Hippo/YAP axis and cancer progression. In order to understand the potential mechanisms of ubiquitination and deubiquitination process in YAP function, we carried out siRNA screening for critical deubiquitinases in TNBC. Via the deubiquitinases (DUB) library, we identified Ubiquitin Specific Peptidase 8 (USP8) as an important effector in YAP function and TNBC progression. Inhibition of USP8 hampered TNBC progression via Hippo signaling. Clinical data revealed that USP8 expression correlated with YAP protein level and poor survival in TNBC patients. Biochemical evaluations revealed that USP8 has the ability to connect with YAP and suppress K48-linked polyubiquitination, thereby enhancing the stability of YAP. Interestingly, YAP directly binds to the USP8 promoter region, enhancing its transcription in TNBC. Our study revealed a forward feedback loop between USP8 and Hippo signaling in TNBC, indicating USP8 as a potential therapeutic drug targets in TNBC.

## Linked entities

- **Genes:** USP8 (ubiquitin specific peptidase 8) [NCBI Gene 9101], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413]
- **Proteins:** YAP1 (Yes1 associated transcriptional regulator)
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** hpo (hippo) [NCBI Gene 37247] {aka CG11228, Dmel\CG11228, Hippo, Hpo/Wts, MST, MST2}, FOSL1 (FOS like 1, AP-1 transcription factor subunit) [NCBI Gene 8061] {aka FRA, FRA1, fra-1}, USP8 (ubiquitin specific peptidase 8) [NCBI Gene 9101] {aka HumORF8, PITA4, SPG59, UBPY}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CCN1 (cellular communication network factor 1) [NCBI Gene 3491] {aka CYR61, GIG1, IBP-10, IGFBP-10, IGFBP10}, USP7 (ubiquitin specific peptidase 7) [NCBI Gene 7874] {aka C16DELp13.2, DEL16P13.2, HAFOUS, HAUSP, TEF1}, FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2354] {aka AP-1, G0S3, GOS3, GOSB}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, OTUB1 (OTU deubiquitinase, ubiquitin aldehyde binding 1) [NCBI Gene 55611] {aka HSPC263, OTB1, OTU1}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, Usp8 (ubiquitin specific peptidase 8) [NCBI Gene 84092] {aka Ubpy, mKIAA0055}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, TEAD4 (TEA domain transcription factor 4) [NCBI Gene 7004] {aka EFTR-2, RTEF1, TCF13L1, TEF-3, TEF3, TEFR-1}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, Taz (Tafazzin) [NCBI Gene 36405] {aka CG8766, Dmel\CG8766, dTAZ, dTaz, tafazzin}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}
- **Diseases:** oral mucositis (MESH:D013280), tumorigenic (MESH:D002471), cancer (MESH:D009369), hematological toxicity (MESH:D006402), dry skin (MESH:D015352), rash (MESH:D005076), carcinogenic (MESH:D011230), TNBC (MESH:D064726), tumorigenesis (MESH:D063646), Breast cancer (MESH:D001943), Parkinson's disease (MESH:D010300), anorexia (MESH:D000855), itching (MESH:D011537), diarrhea (MESH:D003967), epidermal and gastrointestinal toxicities (MESH:D005767), headaches (MESH:D006261), metastasis (MESH:D009362)
- **Chemicals:** glycine (MESH:D005998), PTX (MESH:D017239), EdU (MESH:C022811), GU-104705 (-), cortisol (MESH:D006854), agarose (MESH:D012685), PI (MESH:D010716), DAPI (MESH:C007293), methanol (MESH:D000432), SDS (MESH:D012967), MG132 (MESH:C072553), Cycloheximide (MESH:D003513), CHX (MESH:D003514), Verteporfin (MESH:D000077362), CCK8 (MESH:D012844), hydrogen (MESH:D006859), hematoxylin (MESH:D006416), crystal violet (MESH:D005840), PBS (MESH:D007854), Lipofectamine (MESH:C086724), DAB (MESH:C000469), MTT (MESH:C070243), paraffin (MESH:D010232), PVDF (MESH:C024865), EDTA (MESH:D004492), streptomycin (MESH:D013307), DMSO (MESH:D004121), Hoechst 33342 (MESH:C017807), Triton X-100 (MESH:D017830), IP (MESH:C041508), paraformaldehyde (MESH:C003043), penicillin (MESH:D010406)
- **Species:** Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Drosophila melanogaster (fruit fly, species) [taxon 7227]
- **Mutations:** K342R, K254R, K321R, K48R, K97R, K90R, K315R, K76, K497R, K63, K280R, K494R, K181R, K252R, K204R, K342, C786A, K48
- **Cell lines:** pLKO.1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), BALB — Mus musculus (Mouse), Transformed cell line (CVCL_4350), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), H-J — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_M891), C10310-1 — Homo sapiens (Human), Finite cell line (CVCL_W011), CCK8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873), MMTV — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_KS75), BT549 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_1092), L-N — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0462)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12830590/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12830590/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12830590/full.md

---
Source: https://tomesphere.com/paper/PMC12830590